SCHEMBL1443289

SCHEMBL1443289

N#Cc1ccc(-c2ccc3ncc(N4CCOCC4)nc3c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 2/20 0.48
▸ PIK3CA P42336 3/20 0.48
▸ PRKDC P78527 3/20 0.48
▸ PIK3CD O00329 2/20 0.48
▸ PIK3CB P42338 2/20 0.48
▸ MTOR P42345 2/20 0.48
▸ PIK3CG P48736 2/20 0.48
▸ PIK3C3 Q8NEB9 1/20 0.48
▸ PIM1 P11309 1/20 0.46
▸ CDK6 Q00534 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ ATM Q13315 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ AR P10275 1/20 0.45
▸ CSF1R P07333 1/20 0.45
▸ KIT P10721 1/20 0.45
▸ JAK2 O60674 1/20 0.43
▸ EGLN1 Q9GZT9 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ HRH2 P25021 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1443007 0.90 PDE4D (0.55) LRRK2PIK3CAPRKDCPIK3CDPIK3CB
SCHEMBL3091537 0.88 PIK3CA (0.55) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL1442452 0.88 EGLN2 (0.48) LRRK2PIK3CAPIK3CDPIK3CBMTOR
SCHEMBL12812428 0.86 CDK6 (0.54) LRRK2PIK3CAPRKDCPIK3CDPIK3CB
SCHEMBL13276494 0.85 PIK3CA (0.49) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL1442062 0.85 HTT (0.57) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL1443423 0.85 HTT (0.57) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL13277399 0.84 CYP11B1 (0.52) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL1441997 0.84 PIK3CA (0.51) PIK3CAPRKDCPIK3CDPIK3CBMTOR
SCHEMBL3088623 0.84 MAPK10 (0.51) LRRK2PIK3CAPRKDCPIK3CDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 — — US claimed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 — — US claimed
EP-2473498-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2012-07-11 — — EP claimed
WO-2011026579-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-10 — — WO claimed
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 — — US disclosed
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 — — US disclosed
US-9340528-B2 Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-05-17 — — US disclosed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 — — US disclosed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 — — US disclosed
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-10-18 — — US disclosed
WO-2011026579-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120263708-A1 SUBSTITUTED AMINOQUINOXALINES AS TYROSINE THREONINE KINASE INHIBITORS ABL1, TYK2, JAK2 LRRK2 32/4885PIK3CA 181/4885PRKDC 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback